Announcement • Apr 20
Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 11, 2026 Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 11, 2026, at 14:00 China Standard Time. Location: 3F, Block A, No. 51, Xinpei Road, Jiading District, Shanghai China Announcement • Mar 31
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q1, 2026 Results on Apr 27, 2026 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 Reported Earnings • Oct 28
Third quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.025 loss in 3Q 2024) Third quarter 2025 results: CN¥0.009 loss per share (improved from CN¥0.025 loss in 3Q 2024). Revenue: CN¥62.1m (up 43% from 3Q 2024). Net loss: CN¥14.7m (loss narrowed 56% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Announcement • Jul 02
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 Reported Earnings • Apr 23
Full year 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in FY 2023) Full year 2024 results: CN¥0.10 loss per share (improved from CN¥0.31 loss in FY 2023). Revenue: CN¥280.0m (up 21% from FY 2023). Net loss: CN¥155.1m (loss narrowed 67% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Apr 22
Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 16, 2025 Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: 3F, Block A, No. 51, Xinpei Road, Jiading District, Shanghai China Announcement • Mar 31
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025 New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥42m free cash flow). Earnings have declined by 5.1% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change). Announcement • Dec 31
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025 Reported Earnings • Oct 28
Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.035 loss in 3Q 2023) Third quarter 2024 results: CN¥0.025 loss per share (improved from CN¥0.035 loss in 3Q 2023). Revenue: CN¥43.4m (up 13% from 3Q 2023). Net loss: CN¥33.5m (loss narrowed 37% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. New Risk • Oct 27
New major risk - Revenue and earnings growth Earnings have declined by 4.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥49m free cash flow). Earnings have declined by 4.4% per year over the past 5 years. Announcement • Sep 30
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q3, 2024 results on Oct 28, 2024 Reported Earnings • Aug 23
Second quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.039 loss in 2Q 2023) Second quarter 2024 results: CN¥0.01 loss per share (improved from CN¥0.039 loss in 2Q 2023). Revenue: CN¥52.9m (down 58% from 2Q 2023). Net loss: CN¥13.6m (loss narrowed 77% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Announcement • Jun 29
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 New Risk • Apr 26
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CN¥59m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Announcement • Apr 26
Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 21, 2024 Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 21, 2024, at 14:00 China Standard Time. Location: 3F, Block A, No. 51, Xinpei Road, Jiading District, Shanghai China Reported Earnings • Apr 25
Full year 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.30 loss in FY 2022) Full year 2023 results: CN¥0.31 loss per share (further deteriorated from CN¥0.30 loss in FY 2022). Revenue: CN¥231.1m (down 14% from FY 2022). Net loss: CN¥467.3m (loss widened 2.7% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CN¥115m free cash flow). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Mar 30
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Board Change • Jan 13
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Chang Lian Li was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Dec 30
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.019 loss in 3Q 2022) Third quarter 2023 results: CN¥0.035 loss per share (further deteriorated from CN¥0.019 loss in 3Q 2022). Revenue: CN¥38.5m (down 42% from 3Q 2022). Net loss: CN¥53.4m (loss widened 92% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Oct 11
Jiangsu Huifeng Bio Agriculture Co., Ltd. Approves Board Elections Jiangsu Huifeng Bio Agriculture Co., Ltd. at its EGM held on October 9,2023 approved election of Leng Panpan as non-independent director and Shi Weifeng as non-employee supervisors. Announcement • Sep 30
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 25
Second quarter 2023 earnings released: CN¥0.039 loss per share (vs CN¥0.039 loss in 2Q 2022) Second quarter 2023 results: CN¥0.039 loss per share (in line with 2Q 2022). Revenue: CN¥125.6m (up 73% from 2Q 2022). Net loss: CN¥59.3m (loss widened 1.6% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. New Risk • Jul 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jul 01
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Reported Earnings • Apr 28
Full year 2022 earnings released: CN¥0.30 loss per share (vs CN¥0.20 profit in FY 2021) Full year 2022 results: CN¥0.30 loss per share (down from CN¥0.20 profit in FY 2021). Revenue: CN¥267.5m (down 76% from FY 2021). Net loss: CN¥455.0m (down 248% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent There are 9 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 9 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Zhaoquan Yang is the most experienced director on the board, commencing their role in 2020. Independent Director Chang Lian Li was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 27
Third quarter 2022 earnings released: CN¥0.019 loss per share (vs CN¥0.012 loss in 3Q 2021) Third quarter 2022 results: CN¥0.019 loss per share (further deteriorated from CN¥0.012 loss in 3Q 2021). Revenue: CN¥66.3m (down 50% from 3Q 2021). Net loss: CN¥27.8m (loss widened 54% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.35 profit in 2Q 2021) Second quarter 2022 results: CN¥0.039 loss per share (down from CN¥0.35 profit in 2Q 2021). Revenue: CN¥72.7m (down 74% from 2Q 2021). Net loss: CN¥58.4m (down 111% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Jun 17
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Rongjun Hua was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥3.76, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 26x in the Chemicals industry in China. Total returns to shareholders of 21% over the past three years. Reported Earnings • Apr 27
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.013 (up from CN¥0.009 loss in 1Q 2021). Revenue: CN¥64.1m (down 85% from 1Q 2021). Net income: CN¥20.0m (up CN¥33.0m from 1Q 2021). Profit margin: 31% (up from net loss in 1Q 2021). The move to profitability was driven by lower expenses. Revenue exceeded analyst estimates by 9.2%. Earnings per share (EPS) missed analyst estimates by 1.3%. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Apr 24
Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 26, 2022 Jiangsu Huifeng Bio Agriculture Co., Ltd., Annual General Meeting, May 26, 2022, at 14:00 China Standard Time. Agenda: To consider and approve 2021 work report of the board of directors; 2021 work report of the supervisory committee; 2021 annual accounts; 2021 annual report and its summary; 2021 profit distribution plan; and to discuss other matters. Announcement • Aug 27
Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) signed an Equity Transfer Agreement to acquire additional 81.4107% stake in Nongyi E-commerce (Beijing) Co., Ltd. from Yancheng Nongyi Investment Management Partnership Enterprise (Limited Partnership) for approximately CNY 130 million. Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) signed an Equity Transfer Agreement to acquire additional 81.4107% stake in Nongyi E-commerce (Beijing) Co., Ltd. from Yancheng Nongyi Investment Management Partnership Enterprise (Limited Partnership) for approximately CNY 130 million on August 25, 2021. As per terms of transaction, Post completion, Jiangsu Huifeng Bio Agriculture Co., Ltd. will hold 99.4% stake and Yancheng Nongyi Investment Management Partnership Enterprise (Limited Partnership) will hold no stake in Nongyi E-commerce (Beijing) Co., Ltd. As on June 30, 2021, Nongyi E-commerce (Beijing) Co., Ltd. Reported total assets of CNY 69.7 million, net assets of CNY -71.8 million, Revenue of CNY 91.3 million and net profit of CNY 8 million. Transaction is approved by the Board of Jiangsu Huifeng Bio Agriculture Co., Ltd. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.016 in 2Q 2020) Second quarter 2021 results: Revenue: CN¥283.2m (down 44% from 2Q 2020). Net income: CN¥558.3m (up CN¥531.1m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • May 02
First quarter 2021 earnings released: CN¥0.009 loss per share (vs CN¥0.05 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CN¥437.4m (up 67% from 1Q 2020). Net loss: CN¥13.0m (loss narrowed 83% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.33 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.64b (up 34% from FY 2019). Net income: CN¥41.6m (up CN¥545.5m from FY 2019). Profit margin: 2.5% (up from net loss in FY 2019). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 15
New 90-day low: CN¥2.63 The company is down 19% from its price of CN¥3.24 on 16 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Nov 04
New 90-day low: CN¥3.01 The company is down 12% from its price of CN¥3.43 on 06 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period. Announcement • Oct 30
ADAMA Ltd. (SZSE:000553) signed an agreement to acquire 51% stake in Jiangsu Kelinong Co., Ltd. from Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) for approximately CNY 850 million. ADAMA Ltd. (SZSE:000553) signed an agreement to acquire 51% stake in Jiangsu Kelinong Co., Ltd. from Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) for approximately CNY 850 million on October 29, 2020. The total cash consideration for both Shanghai Dibai Plant Protection Co., Ltd. and Jiangsu Kelinong Co., Ltd. is approximately CNY 1.2 billion. Post completion, ADAMA Ltd. will hold acquire 51% stake in Jiangsu Kelinong Co., Ltd. In a related transaction, ADAMA Ltd. signed an agreement to acquire 1% of Shanghai Dibai Plant Protection Co., Ltd. from Jiangsu Huifeng Bio Agriculture Co., Ltd. on October 29, 2020. Jiangsu Kelinong Co., Ltd. reported total assets of CNY 1.88 billion and net assets of CNY 1.45 billion as of May 31, 2020. Closing is subject to customary closing conditions, including regulatory and other corporate approvals, and is further subject to full resumption of production at the relevant facilities of Huifeng. The transaction is also subject to approval of shareholders of Jiangsu Huifeng Bio Agriculture Co., Ltd. The transaction is approved by the Board of ADAMA Ltd. Huaying Securities Co., Ltd. acted as independent financial advisor, AllBright Law Offices acted as legal advisor and Pan-China Certified Public Accountants LLP acted as accountant for Jiangsu Huifeng Bio Agriculture in the transaction. Reported Earnings • Oct 20
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥166.0m, with losses narrowing by 66% from the prior year. Total revenue was CN¥1.46b over the last 12 months, up 25% from the prior year. Announcement • Oct 16
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report Q3, 2020 results on Oct 20, 2020 Is New 90 Day High Low • Oct 15
New 90-day high: CN¥3.64 The company is up 29% from its price of CN¥2.82 on 17 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. Announcement • Oct 13
Jiangsu Huifeng Bio Agriculture Co., Ltd. Announces Board Election Jiangsu Huifeng Bio Agriculture Co., Ltd. at the EGM to held on October 9, 2020, elected Pei Baiping and Wei Guangquan as non-independent directors. The company elected Li Changlian, Yang Zhaoquan and Hua Rongjun as independent directors. Announcement • Aug 07
Kunshan Fumao Venture Capital Partnership (Limited Partnership) agreed to acquire 7.4% stake in Nanjing Xuankai Biological Technology Co., Ltd. from Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) on August 4, 2020. Kunshan Fumao Venture Capital Partnership (Limited Partnership) agreed to acquire 7.4% stake in Nanjing Xuankai Biological Technology Co., Ltd. from Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) on August 4, 2020. The consideration to be paid within 7 days from signing this agreement. The board of directors of Jiangsu Huifeng Bio Agriculture Co., Ltd. approved the transaction. Announcement • Aug 06
Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) acquired unknown minority stake in Nanjing Xuankai Biological Technology Co., Ltd. for CNY 38 million. Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) acquired unknown minority stake in Nanjing Xuankai Biological Technology Co., Ltd. for CNY 38 million in December 2017. Post transaction Jiangsu Huifeng Bio Agriculture Co., Ltd. will hold 19% stake in Nanjing Xuankai Biological Technology Co., Ltd.
Jiangsu Huifeng Bio Agriculture Co., Ltd. (SZSE:002496) completed the acquisition of unknown minority stake in Nanjing Xuankai Biological Technology Co., Ltd. in December 2017. Announcement • Jul 25
Jiangsu Huifeng Bio Agriculture Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020 Jiangsu Huifeng Bio Agriculture Co., Ltd. announced that they will report first half, 2020 results on Aug 21, 2020 